You've been prescribed BRAVELLE^®, the only follicle-stimulating hormone (FSH) with efficacy and safety data in mixed protocol, letting you mix BRAVELLE^® and hMG in a single syringe for a single injection a day treatment regimen. In clinical testing, when BRAVELLE^® was used in a single-shot mixture of hormones, it resulted in pregnancy rates up to 30% higher than the national average.^1,2

BRAVELLE^® can be administered by subcutaneous (SC) or intramuscular (IM) injections and is used for women undergoing ovulation induction and multiple follicular development in those who are able to produce and release eggs (ovulate).

BRAVELLE^® is a highly purified preparation of human follicle FSH, containing 75 IUs FSH with 2% luteinizing hormone (LH) activity. BRAVELLE^® stimulates eggs to mature in women whose ovaries are basically healthy but are unable to develop eggs. It is not used by women who suffer from ovarian failure.

BRAVELLE^® is usually used together with human chorionic gonadotropin (hCG), and is indicated for ovulation induction following pituitary suppression and multiple follicular development following pituitary suppression.

In Assisted Reproductive Technology (ART), BRAVELLE^® is unique in that it is the only FSH designed to be a partner to hMG. Widely studied for safety and effectiveness in mixed protocol, patients can mix hMG and BRAVELLE^® in 1 syringe and administer 1 injection a day¹. Only BRAVELLE^® demonstrates efficacy across a wide range of patient types (younger patients³, older patients⁴, donor oocyte patients⁵, elevated body mass index (BMI) patients⁶).

BRAVELLE^® is available by prescription in 5mL vials containing 75 IU FSH with accompanying diluent.

Please note:
Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe BRAVELLE^®. It is a potent gonadotropic substance capable of causing mild to severe adverse reactions in women. Gonadotropin therapy requires a certain time commitment by physicians and supportive health professionals, and its use requires the availability of appropriate monitoring facilities. In female patients it must be used with a great deal of care.

BRAVELLE^®, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (incidence of 3.8%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

Please click here to see the side effects, contraindications, and other full Prescribing Information.

References: 1. Keye WR Jr, Marrs RP, Check JH, et al, for the EMBRACE Study Group. Evaluation of mixed protocols with BRAVELLE (human-derived FSH) and REPRONEX (hMG) to assess clinical efficacy (EMBRACE) in women undergoing in vitro fertilization. Fertil Steril. 2004;82:348-357. Centers for Disease Control and Prevention. 2001 Assisted Reproductive Technology Success Rates. National Summary and Fertility Clinical Reports. Available at: www.cdc.gov/ART/ARTO1/section2a.htm#f10. Accessed December 8, 2006. 3. Marrs RP, Check JH, Schnell VL, et al, for the EMBRACE Study Group. Evaluation of mixed protocols with Bravelle (hFSH) and Repronex (hMG) to assess clinical efficacy (EMBRACE I) in patients (18-33 years) undergoing in vitro fertilization. Fertil Steril. 2003;79(suppl 2):S14-S15. Abstract P-10. 4. Keye WR Jr, Surrey MW, Van Voorhis BJ, et al, for the EMBRACE Study Group. Evaluation of mixed protocols with Bravelle (hFSH) and Repronex (hMG) to assess clinical efficacy (EMBRACE II) in patients (34-40 years) undergoing in vitro fertilization. Fertil Steril. 2003;79(suppl 2):S6-S7. Abstract O-3. 5. Kaufman RA, Gocial B, Crain JL, et al. Bravelle, a new, highly purified, human-derived FSH is effective and well tolerated in females participating as oocyte donors for in vitro fertilization. Today’s Ther Trends.2003;21:1-14. 6. Data on file, Ferring Pharmaceuticals, Inc.

Previous: Learning About our Medications

Next: Injecting BRAVELLE®